COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
CellCentric is a clinical-stage biotechnology company advancing inobrodib, an orally bioavailable p300/CBP inhibitor, in registration-enabling trials for relapsed/refractory multiple myeloma.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
